Epilepsy Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight's, "Epilepsy Pipeline Insight, 2025" report provides comprehensive insights about 75+ companies and 90+ pipeline drugs in Epilepsy pipeline landscape. It covers the Epilepsy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Epilepsy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Epilepsy pipeline products in this space.

Explore our latest breakthroughs in Epilepsy Research. Learn more about our innovative pipeline today! @ Epilepsy Pipeline Outlook [https://www.delveinsight.com/sample-request/epilepsy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Epilepsy Pipeline Report

* On 28 August 2025, UCB Biopharma SRL announced a study is to assess the long-term use of lacosamide oral solution dosed at 2 mg/kg/day to 12 mg/kg/day when administered to pediatric study participants with epilepsy who have completed NCT01964560 (EP0034) or NCT00938912 (SP848).
* On 21 August 2025, Praxis Precision Medicines conducted a Clinical Trial to Investigate the Efficacy and Safety of Elsunersen in Pediatric Participants with Early Onset SCN2A Developmental and Epileptic Encephalopathy
* DelveInsight's Epilepsy pipeline report depicts a robust space with 75+ active players working to develop 90+ pipeline therapies for Epilepsy treatment.
* The leading Epilepsy Companies such as UCB, SK Life Science, Stoke Therapeutics, Xenon Pharmaceuticals, Epygenix, Bright Minds Biosciences, Neurona Therapeutics, Cevevel Therapeutics, PTC Therapeutics, Addex Pharmaceuticals, Equilibre Biopharmaceuticals B.V., ES Therapeutics Australia Pty Ltd, Overseas Pharmaceuticals, Anavex Life Sciences, Eliem Therapeutics, Ovid Therapeutics, CAMP4 Therapeutics, LifeSplice, Virpax Pharmaceuticals, Neuroene Therapeutics and others.
* Promising Epilepsy Pipeline Therapies such as Stiripentol, Lacosamide, Levetiracetam 250 mg, Cenobamate, Ganaxolone, Pregabalin , and others.

Stay informed about the cutting-edge advancements in Epilepsy treatments. Download for updates and be a part of the revolution in Neurology Care @ Epilepsy Clinical Trials Assessment [https://www.delveinsight.com/sample-request/epilepsy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Epilepsy Emerging Drugs Profile

* EPX-100: Harmony Biosciences

EPX-100 is a potential new treatment being for people with Dravet syndrome and Lennox-Gastaut Syndrome. EPX-100 is a repurposed antihistamine, which was used in the 1950s and 1960s to treat itchiness. The medication is thought to be able to suppress seizures through its action on the serotonin signaling pathways, a mechanism that is different from its anti-histaminic properties. Serotonin is a chemical messenger present in many parts of the brain. Scientists think that people with Dravet syndrome and Lennox-Gastaut Syndrome may have alterations in the serotonin signaling pathway, but the exact problems are not known. Likewise, precisely how EPX-100 affects serotonin systems in the brain to reduce seizures is still unclear. According to company's pipeline the drug is in the Phase III stage of its development for the treatment of Dravet syndrome and is in the Phase II stage of its development for the treatment of Lennox-Gastaut Syndrome.

* BMB-101: Bright Minds Biosciences

BMB-101, a 5-HT2C selective and biased agonist, has demonstrated compelling activity in a host of in-vitro and in-vivo non-clinical tests. Compared to Locaserin, BMB-101 exhibits strong Gq signaling coupled with minimal beta-arrestin recruitment. Mechanistically, Serotonin (5- Hydroxytryptamine, 5-HT) is a monoamine neurotransmitter widely expressed in the central nervous system, and drugs modulating 5-HT have made a major impact in mental health disorders. Central 5-HT systems have long been associated with the control of ingestive behavior and the modulation of behavioral effects of psychostimulants, opioids, alcohol and nicotine. Results of clinical trials and animal studies indicate that 5-HT2C up receptor agonists may have therapeutic potential in the treatment of addiction by decreasing the intake of opioids as well as impulsive behavior that can escalate compulsive drug use. Currently the drug is in Phase II stage of Clinical trial evaluation for the treatment of Epilepsy.

* STK-001: Stoke Therapeutics

STK-001 is an investigational new medicine for the treatment of Dravet syndrome currently being evaluated in ongoing clinical trials. Stoke believes that STK-001, a proprietary antisense oligonucleotide (ASO), has the potential to be the first disease-modifying therapy to address the genetic cause of Dravet syndrome. STK-001 is designed to upregulate NaV1.1 protein expression by leveraging the non-mutant (wild-type) copy of the SCN1A gene to restore physiological NaV1.1 levels, thereby reducing both occurrence of seizures and significant non-seizure comorbidities. Currently the drug is in Phase III stage of Clinical trial evaluation for the treatment of Dravet Syndrome.

* NRTX-1001: Neurona Therapeutics

NRTX-1001 inhibitory neurons are targeted to the seizure-onset zone to enhance GABAergic inhibition, reduce seizure activity, and repair the affected neural network. NRTX-1001 is delivered as a single, one-time dose and is intended to persist and provide long-term seizure suppression. In preclinical studies, NRTX-1001 has provided seizure-freedom to the majority of the cell treatment group and has not shown signs of dose-limiting toxicity. The preclinical safety and efficacy data have led to an FDA-cleared Phase I/II clinical trial of NRTX-1001 for drug-resistant temporal lobe epilepsy.

* IAMA-6: IAMA Therapeutics

IAMA-6 is an orally administered small molecule therapeutics designed to directly target and inhibit NKCC1-associated neuronal hyperexcitability. The elevated activity of NKCC1 is implicated in various pathological conditions, underscoring the significant potential of NKCC1 inhibition in the treatment of both idiopathic and secondary forms of autism (autism spectrum disorder, or ASD), refractory epilepsy, Dravet Syndrome, and other neurological disorders. With the capability to be applied across multiple central nervous system (CNS) indications, IAMA-6 has demonstrated its safety and favorable tolerability in pre-clinical studies. Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Epilepsy.

The Epilepsy Pipeline Report provides insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Epilepsy with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Epilepsy Treatment.
* Epilepsy Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Epilepsy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Epilepsy market.

Learn more about Epilepsy Drugs opportunities in our groundbreaking Epilepsy research and development projects @ Epilepsy Unmet Needs [https://www.delveinsight.com/sample-request/epilepsy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Epilepsy Companies

UCB, SK Life Science, Stoke Therapeutics, Xenon Pharmaceuticals, Epygenix, Bright Minds Biosciences, Neurona Therapeutics, Cevevel Therapeutics, PTC Therapeutics, Addex Pharmaceuticals, Equilibre Biopharmaceuticals B.V., ES Therapeutics Australia Pty Ltd, Overseas Pharmaceuticals, Anavex Life Sciences, Eliem Therapeutics, Ovid Therapeutics, CAMP4 Therapeutics, LifeSplice, Virpax Pharmaceuticals, Neuroene Therapeutics and others.

Epilepsy Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical

Epilepsy Products have been categorized under various Molecule types such as

* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy

Discover the latest advancements in Epilepsy treatment by visiting our website. Stay informed about how we're transforming the future of Neurology @ Epilepsy Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/epilepsy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Epilepsy Pipeline Report

* Coverage- Global
* Epilepsy Companies- UCB, SK Life Science, Stoke Therapeutics, Xenon Pharmaceuticals, Epygenix, Bright Minds Biosciences, Neurona Therapeutics, Cevevel Therapeutics, PTC Therapeutics, Addex Pharmaceuticals, Equilibre Biopharmaceuticals B.V., ES Therapeutics Australia Pty Ltd, Overseas Pharmaceuticals, Anavex Life Sciences, Eliem Therapeutics, Ovid Therapeutics, CAMP4 Therapeutics, LifeSplice, Virpax Pharmaceuticals, Neuroene Therapeutics and others.
* Epilepsy Pipeline Therapies- Stiripentol, Lacosamide, Levetiracetam 250 mg, Cenobamate, Ganaxolone, Pregabalin , and others.
* Epilepsy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Epilepsy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Epilepsy Pipeline on our website @ Epilepsy Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/epilepsy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Epilepsy: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Epilepsy- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* EPX-100: Harmony Biosciences
* Mid Stage Products (Phase II)
* BMB-101: Bright Minds Biosciences
* Early Stage Products (Phase I)
* IAMA-6: IAMA Therapeutics
* Preclinical and Discovery Stage Products
* NT102: Neuroene Therapeutics
* Inactive Products
* Epilepsy Key Companies
* Epilepsy Key Products
* Epilepsy- Unmet Needs
* Epilepsy- Market Drivers and Barriers
* Epilepsy- Future Perspectives and Conclusion
* Epilepsy Analyst Views
* Epilepsy Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=epilepsy-pipeline-outlook-2025-clinical-trial-studies-ema-pdma-fda-approvals-moa-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/epilepsy-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.